• Home
  • Editorial Board
  • Articles
    • Editorials
    • Guest Articles
  • News
    • Featured
    • Biotech News
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues – Archives
  • Subscribe
  • Contact
Facebook Twitter Instagram
Trending
  • India’s Biotech Bubble: A Critical Look at ABLE & DBT-BIRAC’s BER 2024 Claims
  • The Students’ Federation of India strongly opposed the merger of the CSIR-UGC NET and DBT-BET
  • Scientist demand CBI investigation in Padma Shri scientist Subbanna Ayyappan demise case
  • Special Issue-Exclusive coverage of BRIC-NIAB
  • India’s Rare Disease updates by Prof. Ramaiah Muthyala
  • Indian Scientists published positive results of first in nation ‘Hemophilia A’ gene therapy
  • Unlocking the Potential: Microalgae as a Sustainable Aquafeed Ingredient
  • Indian scientists developed World’s only farmers’ suit “Kisan Kavach” which can protect them from harmful pesticides
Wednesday, July 2
Facebook Twitter Instagram LinkedIn
Biotech Express
  • Home
  • Editorial Board
  • Articles
    • Editorials
    • Guest Articles
  • News
    • Featured
    • Biotech News
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    04/01/20241

    Interview: Reach to common man is the heart and soul of India International Science Festival- Dr. Arvind C Ranade Chief Coordinator, IISF- 2023

    Recent
    04/01/2024

    Interview: Reach to common man is the heart and soul of India International Science Festival- Dr. Arvind C Ranade Chief Coordinator, IISF- 2023

    22/05/2023

    Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society

    26/07/2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

  • Issues – Archives
  • Subscribe
  • Contact
Biotech Express
You are at:Home»Controversial»Undisclosed industry payments rampant in drug-trial papers in Australia

Undisclosed industry payments rampant in drug-trial papers in Australia

0
By Biotech Express on 29/03/2022 Controversial, SARS- CoV2 & COVID-19 Updates

One in four Australian medical researchers involved in drug trials failed to declare money they had received from pharmaceutical companies when submitting journal manuscripts, a study reports.

The authors cross-checked statements on financial conflicts of interest listed by Australian authors of 120 drug trials published in the first eight months of 2020 against a database of company-made payments reported to Medicines Australia, the country’s pharmaceutical-industry association. The research, published in the Journal of General Internal Medicine1 this month, is one of only a few studies outside the United States to examine discrepancies between drug-company payments made to health professionals and author disclosure statements.

The study found that missing or incomplete declarations were common. Half of the trials and a quarter of the 323 Australian authors involved had at least one undeclared financial conflict (see ‘Undeclared conflicts’), with undisclosed payments ranging from AU$140 to AU$97,600 (US$100 to US$71,000) for consulting, advisory meetings, speaker fees and education events.

The results are sobering and similar to those from US studies2, which “suggests that the fundamental problem of conflict-of-interest non-disclosure is a persistent one” in clinical research — evident across journals, across countries and over time, says James Baraldi, a neuroscientist at the University of Pittsburgh, Pennsylvania.

The Australian study found that roughly half of the Australian trial investigators with incomplete disclosures failed to declare any conflicts of interest when company reports showed they had been paid, while 43% of trials had partial declarations

Undeclared financial ties are especially concerning in drug trials, in which transparency is paramount given the deep-rooted influence of pharmaceutical-industry funding that can sway prescribing practices3 and distort research outcomes4, adds Mintzes.

Publicly accessible and government-run databases have helped to expose financial ties between the pharmaceutical industry and medical researchers mainly in the United States, where drug companies and device manufacturers have been legally required to report payments to health-care providers since 2014.

Despite this public scrutiny, evidence suggests that medical researchers are continuing to under-report conflicts of interest, which undermines integrity in science, says Cameron Taheri, a physician-researcher at the University of Calgary in Canada. A 2021 meta-analysis of mostly US studies2, led by Taheri, found that, on average, two-thirds of clinical-trial authors omitted at least one financial conflict in published works.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

72% of biomedical researchers think field is facing a reproducibility crisis: Survey

Nobel prize-winner tallies two more retractions, bringing total to 13

Cancer paper retracted 11 years after reported plagiarism

Leave A Reply Cancel Reply

Current Issue – May 2025
Biotech Express – e-ISSN: 2454-6968

Editorial Board

For Authors – Article Submission and Guidelines

Peer Review Policies

License and Copyright

Advertisement

Recent Posts
  • India’s Biotech Bubble: A Critical Look at ABLE & DBT-BIRAC’s BER 2024 Claims 10/06/2025
  • The Students’ Federation of India strongly opposed the merger of the CSIR-UGC NET and DBT-BET 09/06/2025
  • Scientist demand CBI investigation in Padma Shri scientist Subbanna Ayyappan demise case 08/06/2025
  • Special Issue-Exclusive coverage of BRIC-NIAB 15/02/2025
  • India’s Rare Disease updates by Prof. Ramaiah Muthyala 02/01/2025
  • Indian Scientists published positive results of first in nation ‘Hemophilia A’ gene therapy 28/12/2024
  • Unlocking the Potential: Microalgae as a Sustainable Aquafeed Ingredient 27/12/2024
  • Indian scientists developed World’s only farmers’ suit “Kisan Kavach” which can protect them from harmful pesticides 26/12/2024
  • 3 Nobel Prizes in 2024 went to biotech and allied scientists 13/12/2024
  • USFDA approves Biocon Biologics’ biosimilar for Crohn’s disease, psoriasis 01/12/2024
Archives
Categories
  • Articles
  • Biotech News
  • Controversial
  • Editorials
  • Events
  • Featured
  • Guest Articles
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • News-Industry
  • News-Research
  • Policies
  • SARS- CoV2 & COVID-19 Updates
  • Start-ups
About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Submission Policy and Guidelines

Submission policies

 

 

Follow us on Social Media
  • Facebook
  • Twitter
  • YouTube
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2025 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.